Tagged with Gala

Belgium Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities to develop, manufacture and sell medicines.   Despite representing only a mid-size marketplace from an in-country commercial perspective, the comparatively…

Belgium Back home in Belgium after a stellar stint in Big Pharma, Dr Paul Stoffels is now looking to reshape the future of cancer care with the previously struggling biotech he helped co-found in 1999, Galapagos.   Stoffels is a heavyweight of the global pharmaceutical industry and close ally of the…

Belgium Back home in Belgium after a stellar stint in Big Pharma, Dr Paul Stoffels* is now looking to reshape the future of cancer care with the biotech he helped co-found in 1999, Galapagos. In an exclusive conversation with PharmaBoardroom, Dr Stoffels outlines his excitement about a new CAR-T delivery model that…

Americas The Top 15 pharmaceutical companies in the Central America and Caribbean (CENCA) market list is dominated by familiar big pharma players. However, among the liked of Sanofi, Abbott, Bayer, Pfizer, AstraZeneca, and Novartis sits Megalabs – a Latin American player that has been able to establish itself as a regional…

Americas The Top 15 pharma companies in the Central America & Caribbean (CENCA) region’s retail market (Rx & OTC) for 2019 ranked by sales in USD millions. US-headquartered Abbott tops the list, followed by Uruguayan Megalabs, and French firm Sanofi Made with Visme Infographic Maker  

Pharma Providing an all-in-one venue for major corporate conference, seminar, or gala events, Disney Business Solutions at Disneyland Paris provides customized services to meet all clients’ needs. Director Nicolas Dupeux shares the unique amenities and services available that make any event at Disneyland Paris an experience like no other.   What…

Pharma After a successful IPO on Nasdaq in May 2015, Galapagos is ready to continue developing its robust portfolio of clinical-stage breakthrough therapies with the potential to revolutionize existing treatment paradigms. The CEO discusses his current priorities as well as his vision to transform Galapagos into a specialty pharmaceutical company. In…

Galapagos NV Since its founding Galapagos has operated with a hybrid business model which has combined its internal discoveries with service activities. This model has worked quite well as it has now pushed the company into profitability. Would you say that everything has turned out according to plan or have you exceeded…